- Home
- Products
- Services
- Resources
- About Us
- News
- Contact
NIPT Reference Standard
Background
In the field of eugenics, advances in prenatal testing technology have brought hope and peace of mind to countless families. Among them, non-invasive prenatal testing (NIPT), as a revolutionary technology, has quickly become the preferred method for prenatal screening due to its high accuracy, safety and convenience. Before the advent of NIPT, prenatal testing mainly relied on invasive testing methods such as amniocentesis and chorionic villus sampling (CVS). Although these methods are highly accurate, they have certain risks. In order to overcome these limitations, scientists began to explore a safer and more convenient testing method. In 1997, scientists discovered the presence of fetal free DNA (cfDNA) in the peripheral blood of pregnant women, which laid the foundation for non-invasive prenatal testing. In 2011, NIPT was first used in clinical practice, marking the beginning of a new era for prenatal testing.
Introduction
In the process of testing, quality control products and reference products are indispensable. For NIPT testing, CB-Gene has launched chromosome aneuploidy reference products and quality control products, including autosomes and sex chromosomes, as well as microdeletion and microduplication quality control products and reference products. In the future, chimera reference products will be launched one after another.
Classification | Product Name | Cat. No. |
Trisomy 21(47,XX,+21) Reference Standard | CBPJ0001 | |
Trisomy 18(47,XX,+18) Reference Standard | CBPJ0002 | |
Trisomy 21 (47,XY,+21) Reference Standard | CBPJ0009 | |
Trisomy 13 (47,XY,+13) Reference Standard | CBPJ0010 | |
Trisomy 9 (47,XY,+9) Reference Standard | CBPJ0014 | |
Trisomy 21 (47,XY,+21) Reference Standard-2 | CBPJ0016 | |
Klinefelter Syndrome (47，XXY) Reference Standard | CBPJ0005 | |
Trisomy 9 (47,XY,+9,del(9)(q11)) Reference Standard | CBPJ0003 | |
Angelman syndrome (46,XX,del(15)(q11q13)) Reference Standard | CBPJ0006 | |
Prader-Willi syndrome (46,XY,del(15)(q11.2q13)) Reference Standard | CBPJ0007 | |
18P-syndrome (46,XX,del(18)(p11.2)) Reference Standard | CBPJ0008 | |
DiGeorge syndrome (46,XX,del(22)(q11)) Reference Standard | CBPJ0011 | |
18Q-syndrome (46,XX,del(18)(q22)) Reference Standard | CBPJ0013 | |
11q23.3 del (46,XX,del(11)(q23.3)) Reference Standard | CBPJ0015 | |
Angelman syndrome (46,XY,del(15)(q11.2q13.1)) Reference Standard | CBPJ0017 | |
Prader-Willi syndrome (46,XY,del(15)(q11.2q13.1)) Reference Standard | CBPJ0018 | |
Normal Karyotype (46,XY) Reference Standard | CBPJ0004 | |
| Normal Karyotype (46,XX) Reference Standard | CBPJ0024 | |
10%-Trisomy 21 male-Matched, cfDNA Reference Standard | CBPJ0019-1 | |
| 5%-Trisomy 21 male-Matched, cfDNA Reference Standard | CBPJ0019-2 | |
3.5%-Trisomy 21 male-Matched, cfDNA Reference Standard | CBPJ0019-3 | |
| 10%-18Q-syndrome Female-Matched, cfDNA Reference Standard | CBPJ0020-1 | |
5%-18Q-syndrome Female-Matched, cfDNA Reference Standard | CBPJ0020-2 | |
| 3.5%-18Q-syndrome Female-Matched, cfDNA Reference Standard | CBPJ0020-3 | |
10%-ANGELMAN SYNDROME male-Matched, cfDNA Reference Standard | CBPJ0021-1 | |
| 5%-ANGELMAN SYNDROME male-Matched, cfDNA Reference Standard | CBPJ0021-2 | |
3.5%-ANGELMAN SYNDROME male-Matched, cfDNA Reference Standard | CBPJ0021-3 | |
| 10%-PRADER-WILLI SYNDROMEl male-Matched, cfDNA Reference Standard | CBPJ0022-1 | |
5%-PRADER-WILLI SYNDROMEl male-Matched, cfDNA Reference Standard | CBPJ0022-2 | |
| 3.5%-PRADER-WILLI SYNDROMEl male-Matched, cfDNA Reference Standard | CBPJ0022-3 | |
10%-Normal Karyotype Male-Matched, cfDNA Reference Standard | CBPJ0023-1 | |
| 5%-Normal Karyotype Male-Matched, cfDNA Reference Standard | CBPJ0023-2 | |
3.5%-Normal Karyotype Male-Matched, cfDNA Reference Standard | CBPJ0023-3 |
